^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QLS31905

    i
    Other names: QLS31905
    Associations

    News

    Trials
    Company:
    Qilu Pharma
    Drug class:
    CD3 agonist, CLDN18.2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=360, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P2 trial • Metastases
    |
    cisplatin • gemcitabine • capecitabine • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • QLS31905
    1year
    A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=115, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    CLDN18 (Claudin 18)
    |
    cisplatin • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • QLS31905